When dashboard averages break — replace them with pass-through

BoomRx's pricing model is built for procurement scale. The platform markets competitive pricing, a advertised $30 flat-rate cold-chain shipping fee across partners, and about 20% average cost savings versus industry benchmarks — with eligible products, rates, and state shipping availability shown in the provider dashboard after signup. That can produce genuinely strong landed cost at volume, especially when flat-rate shipping replaces variable multi-pharmacy fees. The cost is granularity at the moment of quoting: you see competitive rates inside the hub, but you are still thinking in procurement SKUs and dashboard averages rather than a resolved per-vial number on each patient line before checkout.

A pass-through model inverts that for patient-specific 503A ordering. With Fizy Health, the resolved 503A landed cost appears on each catalog and cart line before you check out, and the platform's margin is a disclosed facilitation fee at payment rather than an opaque per-vial markup buried in the drug cost. The drug cost is what the pharmacy charges; the platform fee is stated separately. For a clinic quoting cash-pay semaglutide or tirzepatide daily, that means the price you quote and the price you pay are the same visible number on each line — with no hidden layer inside the vial cost and no need to mentally adjust for a flat $30 shipping fee spread across a batch.

Replace BoomRx's pricing visibility model when dashboard averages actively slow your patient-facing margin work. Common signals: you delay quoting a new patient because you are not confident in the per-vial landed cost on that specific SKU; you cannot set cash-pay prices at the point of sale because your cost is tied to hub averages rather than line-level pass-through; you suspect platform margin is bundled into the drug cost but cannot separate drug cost from facilitation; or your refill volume has shifted and you are not sure the competitive rate on your top GLP-1 lines still reflects what you actually pay after the $30 shipping allocation.

Another signal is operational, not just financial: if paid orders get rejected after payment for SIG or licensure issues, the pricing question compounds with a validation gap — and a procurement-first hub may not tie every line to a patient with pre-submit checks. A pass-through platform like Fizy Health pairs visible per-vial cost with pre-submit cart validation and HIPAA audit on each patient line, so the same workflow that shows your margin also catches the errors that cost you a refund cycle. If none of these signals apply — your BoomRx dashboard rates and flat-rate shipping are strong and refill day is clean — the hub model may still be the right fit for 503B and brand procurement. Replace it when patient-linked margin clarity, not vendor consolidation, is the constraint.